P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors
Michele Cea,Antonia Cagnetta,Marco Gobbi,Franco Patrone,Paul G. Richardson,Teru Hideshima,Kenneth C. Anderson +6 more
TL;DR: Molecular events underling antitumor effects of HDACIs and the most recent results of clinical trials in relapsed and refractory MM are reviewed to furnish the basis for an innovative therapeutic approach.
Journal ArticleDOI
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Paul G. Richardson,Aurore Perrot,Jesús F. San Miguel,Meral Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,Philippe Moreau,Meletios A. Dimopoulos,Jeffrey Shang Yi Huang,Jiri Minarik,Michele Cavo,H. Miles Prince,Laure Malinge,Franck Dubin,Helgi J. K. Van De Velde,Kenneth C. Anderson +16 more
TL;DR: The ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to pomalidomide-dexamethasone in relapsed and refractory multiple myeloma as discussed by the authors .
Journal ArticleDOI
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.
Guangwu Guo,Guangwu Guo,Noopur Raje,Charles Seifer,Charles Seifer,Jake A. Kloeber,Jake A. Kloeber,Randi Isenhart,Randi Isenhart,Gavin Ha,Gavin Ha,Andrew Yee,Elizabeth O'Donnell,Yu-Tzu Tai,Paul G. Richardson,Giada Bianchi,Jacob P. Laubach,Diane Warren,Erica Gemme,Jordan Voisine,Jordan Voisine,Julia Frede,Julia Frede,Antonis Kokkalis,Antonis Kokkalis,Huiyoung Yun,Huiyoung Yun,Valeriya Dimitrova,Valeriya Dimitrova,Tushara Vijaykumar,Tushara Vijaykumar,Matthew Meyerson,Nikhil C. Munshi,Kenneth C. Anderson,Birgit Knoechel,Birgit Knoechel,Jens G. Lohr +36 more
TL;DR: It is hypothesized that cfDNA can be used to track disease load and clonal evolution of MM, to provide longitudinal genetic information about disease evolution that is not accessible by bone marrow biopsy.
Journal ArticleDOI
A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).
Paul G. Richardson,Asher A. Chanan-Khan,Sagar Lonial,Amrita Krishnan,Melissa Alsina,Michael C. Carroll,Karen Adler,G. F. Cropp,Constantine S. Mitsiades,Robert Johnson,Alison L. Hannah,Kenneth C. Anderson +11 more
TL;DR: Encouraging anti-MM activity has been observed in all dose groups with KOS-953 with BZ ≥ 1.0 mg/m2 and 20S proteasome inhibition was observed in PBMCs prior to D11 infusion, suggesting sustained Hsp90 inhibition on this schedule.
Journal Article
Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation.
David Avigan,Zekui Wu,Jianlin Gong,Robin Joyce,James D. Levine,Anthony D. Elias,Paul G. Richardson,Joya Milano,Leslie Kennedy,Kenneth C. Anderson,Donald Kufe +10 more
TL;DR: In this paper, mobilized peripheral blood progenitor cells (PBPCs) were obtained from 18 patients with locally advanced or metastatic breast cancer preparing to undergo autologous stem cell transplantation.